« Return to News | CROs/Service Providers

SFBC Exits Florida

Thursday, May 18, 2006 02:34 PM

It should comes as no surprise that SFBC is getting out of Florida after its Miami phase I unit performed so poorly last quarter.  Current SFBC officials—the former heads of PharmaNet—needed to stop the bleeding before the whole company was in jeopardy. Its later phase business is still holding its own.

SFBC International decided May 17 to end its early phase business in Florida after county officials wouldn't extend a review of some planned renovations to its troubled Miami phase I unit. The phase I unit has been the subject of numerous stories detailing serious issues with structural safety and questionable recruitment of undocumented workers as trial participants.

SFBC, which earlier this year moved its headquarters to PharmaNet’s HQ in Princeton, N.J., said that its Florida operations, including Ft. Myers, were expected to account for 10% of 2006 revenue. The company also withdrew its financial guidance for 2006.

SFBC officials said they will continue to offer early phase clinical development along with late phase. Now they should get around to a complete transformation by renaming the company PharmaNet.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.